valsartan + nateglinide

Valsartan + nateglinide is a combination of two small molecule drugs, each with distinct mechanisms of action. Valsartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the angiotensin II type 1 (AT1) receptor, leading to vasodilation, reduced aldosterone secretion, decreased cardiac activity, and increased sodium excretion. It is primarily used for managing hypertension and heart failure[1]. Nateglinide is a meglitinide-class oral antihyperglycemic agent that stimulates rapid insulin secretion from pancreatic β-cells by inhibiting ATP-sensitive potassium channels (ABCC8), resulting in membrane depolarization and subsequent calcium influx[8][6]. This mechanism helps control postprandial blood glucose levels in patients with type 2 diabetes mellitus. The combination has been studied in clinical trials such as NAVIGATOR for its effects on progression to diabetes and cardiovascular outcomes in patients with impaired glucose tolerance at high cardiovascular risk[3][4].